- Home
- BCAB
BCAB
BioAtla Inc.
as 05-20-2024 11:33am EST
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
| Founded: | 2007 | Country: | United States |
| Employees: | 65 | City: | SAN DIEGO |
| Market Cap: | 136.2M | IPO Year: | 2020 |
| Target Price: | $14.50 | AVG Volume (30 days): | 644.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.24 - $4.02 | Next Earning Date: | 05-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of BioAtla Inc. (BCAB)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| STEINMAN LAWRENCE | BCAB | Director | Dec 19 '23 | Buy | $2.05 | 20,000 | $41,048.00 | 38,459 | SEC Form 4 |
| MCBRINN SYLVIA | BCAB | Director | Mar 28 '23 | Buy | $2.35 | 4,000 | $9,400.00 | 19,125 | SEC Form 4 |
Latest BioAtla Inc. News
BCAB Breaking Stock News: Dive into BCAB Ticker-Specific Updates for Smart Investing
GuruFocus.com
5 days ago
BioAtla Inc (BCAB) (Q1 2024) Earnings Call Transcript Highlights: Strategic Adjustments and ...
GlobeNewswire
6 days ago
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress
GlobeNewswire
12 days ago
BioAtla to Participate in the Citizens JMP Life Sciences Conference
GlobeNewswire
13 days ago
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024
MT Newswires
14 days ago
BioAtla's Multiple Cancer Drug Candidate Receives FDA Clearance
GlobeNewswire
14 days ago
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors
GlobeNewswire
a month ago
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Simply Wall St.
2 months ago